Aquestive Therapeutics Inc. [NASDAQ: AQST] closed the trading session at $6.61 on 08/11/20. The day’s price range saw the stock hit a low of $6.54, while the highest price level was $7.15. The company report on August 10, 2020 that Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis.
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s drug candidate AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of allergic reactions (Type 1), including anaphylaxis, using Aquestive’s proprietary PharmFilm® technologies.
Fast Track is an FDA process designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill unmet medical needs. Programs with Fast Track designation may benefit from early and frequent communication with the FDA, eligibility for FDA accelerated approval and priority review, if relevant criteria are met, in addition to a rolling submission of the marketing application.
The stocks have a year to date performance of 13.57 percent and weekly performance of 20.40 percent. The stock has been moved at 43.70 percent over the last six months. The stock has performed 57.01 percent around the most recent 30 days and changed 16.17 percent over the most recent 3-months.
If compared to the average trading volume of 1.05M shares, AQST reached to a volume of 1002996 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Aquestive Therapeutics Inc. [AQST]:
H.C. Wainwright have made an estimate for Aquestive Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 22, 2019. While these analysts kept the previous recommendation, Lake Street raised their target price to Buy. The new note on the price target was released on January 03, 2019, representing the official price target for Aquestive Therapeutics Inc. stock. Previously, the target price had yet another raise to $23, while RBC Capital Mkts analysts kept a Outperform rating on AQST stock.
The Average True Range (ATR) for Aquestive Therapeutics Inc. is set at 0.40, with the Price to Sales ratio for AQST stock in the period of the last 12 months amounting to 3.61.
AQST stock trade performance evaluation
Aquestive Therapeutics Inc. [AQST] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.40. With this latest performance, AQST shares gained by 57.01% in over the last four-week period, additionally plugging by 43.70% over the last 6 months – not to mention a rise of 65.66% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AQST stock in for the last two-week period is set at 70.28, with the RSI for the last a single of trading hit 72.03, and the three-weeks RSI is set at 66.28 for Aquestive Therapeutics Inc. [AQST]. The present Moving Average for the last 50 days of trading for this stock 5.16, while it was recorded at 6.37 for the last single week of trading, and 4.75 for the last 200 days.
Aquestive Therapeutics Inc. [AQST]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Aquestive Therapeutics Inc. [AQST] shares currently have an operating margin of -100.11 and a Gross Margin at +61.30. Aquestive Therapeutics Inc.’s Net Margin is presently recorded at -125.92.
Return on Total Capital for AQST is now -94.47, given the latest momentum, and Return on Invested Capital for the company is -123.94. Return on Equity for this stock declined to -3,347.45, with Return on Assets sitting at -80.14. Additionally, AQST Total Debt to Total Capital is recorded at 111.29, with Total Debt to Total Assets ending up at 76.88.
Reflecting on the efficiency of the workforce at the company, Aquestive Therapeutics Inc. [AQST] managed to generate an average of -$285,543 per employee. Receivables Turnover for the company is 5.37 with a Total Asset Turnover recorded at a value of 0.64.Aquestive Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 3.00.
Earnings per share (EPS) analysis for Aquestive Therapeutics Inc. [AQST] stock
With the latest financial reports released by the company, Aquestive Therapeutics Inc. posted -0.74/share EPS, while the average EPS was predicted by analysts to be reported at -0.69/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -7.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AQST.
Aquestive Therapeutics Inc. [AQST]: Insider Ownership positions
There are presently around $115 million, or 53.10% of AQST stock, in the hands of institutional investors. The top three institutional holders of AQST stocks are: BRATTON CAPITAL MANAGEMENT, L.P. with ownership of 11,503,294, which is approximately 0% of the company’s market cap and around 5.70% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 1,750,000 shares of the stock with an approximate value of $11.57 million in AQST stocks shares; and VANGUARD GROUP INC, currently with $4.14 million in AQST stock with ownership of nearly 5.807% of the company’s market capitalization.
Positions in Aquestive Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 28 institutional holders increased their position in Aquestive Therapeutics Inc. [NASDAQ:AQST] by around 1,426,535 shares. Additionally, 35 investors decreased positions by around 3,744,706 shares, while 3 investors held positions by with 12,252,251 shares. The mentioned changes placed institutional holdings at 17,423,492 shares, according to the latest SEC report filing. AQST stock had 9 new institutional investments in for a total of 810,161 shares, while 19 institutional investors sold positions of 2,128,404 shares during the same period.